Arcadia Biosciences, Inc.
RKDA- Exchange
- Nasdaq
- Industry
- Crude Petroleum & Natural Gas
- SEC CIK
- 0001469443
No open-market purchases or sales by Arcadia Biosciences, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $146.5K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:14 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 30, 2022 |
| Revenue | $4.86M | $5.04M | $5.33M | $9.96M | $6.78M |
| Cost of revenue | $3.10M | $2.96M | $3.30M | $9.80M | $8.71M |
| Research and development | $9.00K | $53.0K | $1.39M | $1.51M | $3.89M |
| Selling, general and administrative | $7.00M | $9.64M | $14.5M | $18.0M | $22.9M |
| Operating income | -$2.50M | -$3.65M | -$13.9M | -$18.8M | -$35.5M |
| Interest expense | – | – | – | – | $20.0K |
| Income tax | $8.00K | $8.00K | $8.00K | $14.0K | $2.00K |
| Net income | -$2.34M | -$7.04M | -$14.0M | -$15.4M | -$14.7M |
| EPS, basic | $-1.71 | $-5.17 | – | $-25.65 | – |
| EPS, diluted | $-1.71 | $-5.17 | – | $-25.65 | – |
| Weighted shares, basic | 1.37M | 1.36M | 1.24M | 599.4K | – |
| Weighted shares, diluted | 1.37M | 1.36M | 1.24M | 599.4K | – |
| Margins and growth | |||||
| Operating margin | -51.5% | -72.3% | -261.5% | -189.0% | -524.0% |
| Net margin | -48.1% | -139.5% | -262.3% | -154.4% | -216.2% |
| Revenue growth, year over year | −3.7% | −5.3% | −46.5% | +46.8% | −15.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 30, 2022 |
| Cash and equivalents | $259.0K | $4.24M | $6.52M | $20.6M | $28.7M |
| Short-term investments | $4.30M | $0 | $5.12M | – | – |
| Accounts receivable | – | – | – | – | $1.37M |
| Inventory | $1.21M | $904.0K | $1.96M | $2.57M | $4.43M |
| Total current assets | $6.36M | $9.24M | $15.0M | $25.4M | $35.4M |
| Property, plant and equipment | $8.00K | $41.0K | $384.0K | $704.0K | $2.29M |
| Intangible assets | $39.0K | $39.0K | $39.0K | $40.0K | $484.0K |
| Total assets | $6.55M | $13.5M | $19.7M | $28.9M | $43.9M |
| Short-term debt | – | – | – | – | $0 |
| Total current liabilities | $2.06M | $2.56M | $3.59M | $4.21M | $5.04M |
| Long-term debt | – | – | – | – | $0 |
| Total liabilities | $2.41M | $7.29M | $7.00M | $8.02M | $12.7M |
| Shareholders' equity | $4.14M | $6.22M | $12.7M | $20.9M | $31.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 30, 2022 |
| Operating cash flow | -$4.74M | -$9.63M | -$15.3M | -$14.0M | -$25.9M |
| Capital expenditures | $0 | $16.0K | $5.00K | $72.0K | $1.01M |
| Free cash flow | -$4.74M | -$9.64M | -$15.3M | -$14.0M | -$26.9M |
| Stock-based compensation | $234.0K | $512.0K | $717.0K | $1.11M | $1.54M |
| Investing cash flow | $750.0K | $7.34M | -$4.34M | $1.42M | $16.6M |
| Financing cash flow | $6.00K | $9.00K | $5.51M | $4.52M | $21.9M |
| Net change in cash | -$3.98M | -$2.28M | -$14.1M | -$8.04M | $12.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.8% | 10.1% | 13.5% | 11.1% | 22.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 6, 2026 | 2.41M | +76.2% | SEC |
| May 7, 2026 | 2.06M | +50.5% | SEC |
| Apr 23, 2026 | 2.06M | +50.5% | SEC |
| Mar 19, 2026 | 2.06M | +50.5% | SEC |
| Oct 31, 2025 | 1.37M | +0.6% | SEC |
| Aug 7, 2025 | 1.37M | +0.3% | SEC |
| May 1, 2025 | 1.37M | +0.3% | SEC |
| Apr 23, 2025 | 1.37M | +0.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.